Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 3/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099895 | 0.90 | ALDH1A1 (0.45) | FFAR1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL29318772 | 0.89 | HDAC3 (0.51) | PLAAT3PLAAT5PLAAT2PLAAT4GAA | |
| SCHEMBL106904 | 0.82 | ESR1 (0.50) | GAAHDAC2HDAC8KMT2AMEN1 | |
| SCHEMBL19658332 | 0.82 | ALDH1A1 (0.59) | FFAR1KMT2AMEN1POLBCYP1A2 | |
| SCHEMBL2625210 | 0.82 | FFAR1 (0.51) | PLAAT3PLAAT5PLAAT2PLAAT4FFAR1 | |
| SCHEMBL28675816 | 0.81 | FFAR1 (0.46) | FFAR1KMT2APDPK1POLBCTDSP1 | |
| SCHEMBL6303062 | 0.81 | FFAR1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4FFAR1 | |
| SCHEMBL7639787 | 0.81 | GFER (0.48) | KDM4EALDH1A1 | |
| SCHEMBL7823277 | 0.80 | NPC1 (0.50) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL105766 | 0.80 | ALDH1A1 (0.61) | FFAR1HDAC1HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20150322087-A1 | CEPHALOSPORIN DERIVATIVES AND METHODS OF USE | UNIVERSITY OF KANSAS | 2015-11-12 | — | — | US | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PLAAT3 1089/4885PLAAT5 1674/4885PLAAT2 1792/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PLAAT3 1089/4885PLAAT5 1674/4885PLAAT2 1792/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PLAAT3 1089/4885PLAAT5 1674/4885PLAAT2 1792/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PLAAT3 1089/4885PLAAT5 1674/4885PLAAT2 1792/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PLAAT3 1089/4885PLAAT5 1674/4885PLAAT2 1792/4885 |
| US-20150322087-A1 | CEPHALOSPORIN DERIVATIVES AND METHODS OF USE | CNDP2, CLSPN, PEPD | PLAAT3 2668/4885PLAAT5 1885/4885PLAAT2 2742/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | PLAAT3 1089/4885PLAAT5 1674/4885PLAAT2 1792/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | PLAAT3 655/4885PLAAT5 1664/4885PLAAT2 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.